…Introduction to ADCs in Cancer TherapyThe advent of targeted therapies has revolutionized the field of oncology, offering new hope and…
Browsing: Hematologic Malignancies
Zahra Pakbaz, MD, shed light on a range of critical findings from the American Society of Hematology (ASH) meeting, with…
In 2024, CAR T-cell therapy continues to transform the landscape of treatment for hematologic malignancies, including multiple myeloma and various…
The battle against polycythemia vera (PV), a rare and chronic form of blood cancer, has seen a transformative advancement with…
Dipti Patel-Donnelly, a medical oncologist at the Virginia Cancer Specialists, leads a study titled “How Can We Manage High-Risk Hematologic…
John F. Seymour, MBBS, Ph.D., FRACP, a clinical haematologist and the Director of the Haematology Department at Peter MacCallum Cancer…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology, investigates a combination therapy for…
Hamish Scott, MD, serves as the Head of the Department of Genetics and Molecular Pathology at SA Pathology in Adelaide,…
Rabi Hanna, MD, from the Department of Pediatric Hematology Oncology and BMT at Cleveland Clinic Children’s, conducted a study on…
By: Allen Wilbanks Date: September 27, 2023 Stephen Oh, MD PhD, took the podium to present his research in a…
By: Allen Wilbanks Date: September 27, 2023 Myeloproliferative neoplasms (MPNs) are a group of blood disorders characterized by the overproduction…
By: Allen Wilbanks Date: 09/27/2023 William Shomali, MD, is a respected expert in systemic mastocytosis, known for his collaborative work…
By: Allen Wilbanks Date: 09/27/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content available…
By: Pankit Vachhani, MD Date: 09/22/2023 REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS AML-ALL US – Online content…
When your patient is diagnosed with a blood cancer such as chronic lymphocytic leukemia (CLL), it’s important to remember that…
Phase 3 ITHACA Study Results: Latest Insights on Isatuximab presented from ASH 2022 discussed by Dr. Irene Ghobrial from…
ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus Updates By Stefan O. Ciurea, MD from UCI Health So…
Women with recurrent miscarriage were treated with low molecular weight heparin versus usual pregnancy care By Zahra Pakbaz, MD from…
ASH Meeting 2022 – Hematopoietic Stem Cell Transplantation with Tacrolimus UpdatesBy: Stefan O. Ciurea, MD – Director, Hematopoietic Stem Cell…
2023 ASH Pregnancy Update Slides Etavopivat treatment Low molecular weight heparin versus a standard pregnancy care for women with recurrent…
MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative…
MPN: ASH 2022 Abdulraheem Yacoub Add-on of Parsaclisib By Abdulraheem Yacoub, MD What were the results of the MPN (myeloproliferative…
PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical TrialBy Srdan Verstovsek, MD, PhDWhat were the results of the PTG-300…
iFrame is not supported! PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What…
PTG-300: ASH 2022 Srdan Verstovsek Verify Phase 3 Clinical Trial By Srdan Verstovsek, MD, PhD What were the results of…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help…
Caplacizumab: TMA Camila Masias ASH 2022 HRES Discussion By Camila Masias, MD How will Caplacizumab help patients with TMAs? I…
iFrame is not supported! Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab…
Caplacizumab: TMA Camila Masias ASH 2022 Complement-Mediated HRES Debate By Camila Masias, MD How will Caplacizumab help patients with TMAs?…
iFrame is not supported! VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD,…
VERIFY Trial PV: ASH 2022 Phase 3 Study on PTG-300 Srdan Verstovsek By Srdan Verstovsek, MD, PhD How will the…
iFrame is not supported! Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called…
Efgartigimod By Catherine Broome, MD We presented data on Efgartigimod in a phase three trial called Advanced iv, which looked…
Inherited Thrombophilia: Pregnancy & Heparin – Middeldorp, MD- ASH 2022 By Saskia Middeldorp, MD I’m able to present the results…
iFrame is not supported! Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this…
Omidubicel: Ronit Simantov Phase 3 Results [2022] Blood Cancers What is omidubicel and can this improve clinical outcomes? -…
Prophylactic management of hemophilia continues to be a challenge. This nurse-led activity discusses treatment strategies, safety and efficacy of current…
Aaron T. Gerds, MD, MS, Associate Professor of Medicine, Deputy Director for Clinical Research at the Cleveland Clinic Taussig Cancer…
At this year’s EHA meeting, we presented an abstract from the REVEAL study. Really focusing in on thrombosis risk in…
Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale…
Stephanie Halene, MD, Ph.D., Associate Professor of Medicine (Hematology); Chief, Hematology; Director, DeLuca Center for Innovation in Hematology Research, Yale…
Dr. Aaron Goodman of UCSD speaks with hosts Jack West and Charu Aggarwal explaining the remarkable level of engagement he…
Dr. Mikkael Sekeres of Univ of Miami chats with Charu Aggarwal and Jack West about challenges and opportunities with his…
Ari Melnick, MDof Weill Cornell Medicine discusses winning the  American Society of Hematology Ernest Beutler Lecture and Prize. ASH will award…
Edward J. Benz, Jr., MD at Dana Farber discusses his award from American Society of Hematology Leadership in Promoting Diversity…
Mansoor Raza Mirza, MD from Region Hovedstaden discusses an abstract from ASCO 2020 entitled Final survival analysis of Smita Bhatia,…
Philip McCarthy, MD of Roswell Park discusses New Strategy for Controlling Graft vs. Host Disease in Blood/Marrow Transplant Recipients. New…
Earn CME: https://www.naccme.com/program/20-hemcovid-7 In this webcast, Drs. Joseph R. Mikhael and Michael J. Satlin discuss new updates on the current…
Earn CME: https://www.naccme.com/program/20-hemcovid-5 In this webcast, Dr. Joseph R. Mikhael and patient advocate Yelak Biru discuss ways to limit patient…
Earn CME: https://www.naccme.com/program/20-hemcovid-4 In this webcast, Drs. Joseph R. Mikhael leads a roundtable discussion with Drs. Jessica K. Altman, Michael…
Earn CME: https://www.naccme.com/program/20-hemcovid-1 In this webcast, Drs. Joseph R. Mikhael, John P. Leonard, Nina Shan, and Michael J. Satlin discuss…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Gail J.…
Earn CME: https://www.naccme.com/program/7335-2 In this webcast from the ‘MRD in Hematologic Malignancies: Testing Considerations and Challenges’ symposium, Dr. Prashant Kapoor…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-10 In this webcast from the ‘New and Emerging Agents in Hairy Cell Leukemia (HCL)’ symposium during the…
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during…
Earn CME: https://www.naccme.com/program/19-lm-03 In this webcast from the ‘Minimal Residual Disease in Hematologic Malignancies Testing Considerations and Challenges’ symposium during…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer explains CAR-T treatment in hematological malignancies affecting clinicians and moving forward with the…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer answers commong questions on CAR-T treatment in hematological malignancies and the toxicities used.…
Shebli Atrash, MD @atrashshebli of @atriumhealth @levinecancer discusses CAR-T treatment in hematological malignancies. Â Chemeric antigen receptor (CAR)-T-cell therapy has…
Allison King, MD of Washington University School of Medicine @WUSTLmed answers the gender disparities in hematology research: how this will affect clinicians…
Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the results on gender disparities in hematology research success. ______________ Hematologists…
Allison King, MD of Washington University School of Medicine @WUSTLmed discusses the study on gender disparities in hematology research success. ______________…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells: how does…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell answers a way to enhance the potency of blood-forming stem cells, potentially opening…
Saghi Ghaffari, MD, PhD of @MountSinaiNYC @sinaistemcell discusses a way to enhance the potency of blood-forming stem cells, potentially opening…
Mount Sinai researchers have discovered a way to enhance the potency of blood-forming stem cells, potentially opening the door to…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer explains how oral therapies will impact the treatment…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer considers what we have learned from understanding real-world…
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine @YaleCancer elaborates on the role of venetoclax in treatment…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Jasmine Zain, MD, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center,…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about…
Christopher Yasenchak, MD, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his opinion on zanubrutinib as compared to other second-generation…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews offers his impression of the pivotal clinical data that lead…
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews speculates on therapies for front-line and relapsed mantle cell lymphoma.
Michael Wang, MD, Professor, Department of Lymphoma and Myeloma @MDAndersonNews elaborates on the ZUMA-2 trial investigating anti-CD19 CAR-T cell therapy…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should…
Chaitra Ujjani, MD, Associate Professor, @SeattleCCA University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or…
Constantine Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data…
Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, on the development of a new risk…
Max Topp, MD, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1…
Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope considers…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses…
Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope shares…
Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on…
Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering offers opinion on whether there is sufficient evidence to…
Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society,…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes…
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai discusses whether molecular analysis is appropriate and…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai tells us about his approach to the…
John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai shares outcomes from the MANIFEST study investigating…
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia.
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine describes those patient types more suited for treatment with rasburicase versus allopurinol.
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis…
Kylee Martens, MD Resident Physician, Internal Medicine @UWMedicine considers whether there are particular patient types more prone to tumor lysis…
Ryan Lynch, MD Assistant Professor of Medicine, Hematology/Oncology, University of Washington, @SeattleCCA considers the ideal patient profile for zanubrutinib in…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Frederick Locke, MD Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, provides insight on the real-world evidence presented at ASH 2019 regarding…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of…
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma.
Lori Leslie, MD Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma…
Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews offers his opinion on off-the-shelf…
Michael Jain, MD Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes…
Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews tells us about the outcomes of the US…
Michael Jain, MD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, @MoffittNews discusses how population-based outcomes in…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM shares the…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM explains the…
Timothy Illidge, MD, PhD, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, @OfficialUoM describes the…
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the future of off-the-shelf CAR-T cell therapy.
James Essell, MD, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses off the-shelf CAR natural killer (CAR NK)…
Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI explains some common questions regarding PTEN patients. _________ Cleveland Clinic researchers have…
Charis Eng, MD, Phd @CharisEngMDPhD of @ClevelandClinic @CCLRI clarifies genetic autism in PTEN patients. _______ Cleveland Clinic researchers have identified…
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic speculates on the clinical impact of the TOURMALINE-AL1 study.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the side effects of the TOURMALINE-AL1 study presented at ASH 2019.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the outcomes of the TOURMALINE-AL1 study presented at ASH 2019.
Angela Dispenzieri, MD Hematologist, Department of Hematology, @MayoClinic shares the design of the TOURMALINE-AL1 study presented at ASH 2019.
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Saro Armenian, DO, MPH @cityofhope Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical…
Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in…
Eric Fedyk, PhD of @TakedaPharma discusses the binding of CD38 therapeutics to red blood cells and platelets subverts depletion of…
Christopher Yasenchak, MD of @TheUSONetwork discusses the phase 2 study of frontline brentuximab vedotin plus nivolumab.
BOSTON–(BUSINESS WIRE)–Oct. 3, 2019– Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking…
Program includes debate and interactive case studies on emerging cancer care practices. #NCCNhem19. SAN FRANCISCO, CA [September 10, 2019] — World-renowned experts…
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Using Steroids To Mitigate Cytokine-Release Syndrome: Did Not See Any…
Max S. Topp MD Of University Hospital of Wuerzburg Discusses Mitigate Cytokine-Release Syndrome With Steroids In Practice: If Only 10Of…
Josh Brody MD @joshuabrodyMD Of Icahn School of Medicine at Mount Sinai Discusses Results Of Novel In Situ Vaccine: Vaccine…
Earn CME Credit: https://www.naccme.com/program/7327 Knowledge is evolving regarding numerous clinical aspects of immune thrombocytopenic purpura (ITP), and there remains significant…
Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Newer Agents Coming Out For…
Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Updates On Thrombotic Microangiopathies. At…
Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Atypical Hemolytic Uremic Syndrome. At…
Minh-Ha Tran, D.O. Associate Medical Director, Transfusion Medicine, Pathology at University of California Irvine Discusses Data On TITAN Study &…
Samer Khaled, MD, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses MEDALIST Study. At…
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Andre Goy, MD, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical…
Elizabeth Budde, MD Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses How City…
Frederick Locke, MD Program Co-Leader, Immunology Moffitt Cancer Center, discusses Management Of Toxicity With CAR-T Therapies. At The 60th ASH…
Andrew Pecora, MD Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, discusses Results Of…
Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, ?Center for Discovery and Innovation, Hackensack University, discusses Age-Associated Aberrant…
Rena Feinman, PhD Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center, discusses The Role…
Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses The LEAP Consortium Research Outcomes. At…
Ravi Vij, MD Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine Discusses Data…
Jason Butler, PhD Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, Discusses Leukemia-Initiating Metabolic…
Yana Pikman, M.D. Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Childrens Hospital, Discusses LEAP Consortium In Pediatric Acute Leukemia…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Understanding & Using Combo Approaches With…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progressive Disease After Receiving CAR T…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Progression Of Disease & Treatment At…
Victor Chow M.D. an Oncologist at the University Of Washington in Seattle, Washington discusses Designing Prospective Trials At The 60th…
Victor Chow M.D. an oncologist at the University Of Washington in Seattle, Washington discusses Clinical Trials For The Future At…
Koen Van Besien, M.D. Director of the Stem Cell Transplant Program, Professor of Medicine at Weill Cornell Medical College Discusses…
Ellen Ritchie, M.D. assistant professor of medicine and a member of the Leukemia Program at the Weill Cornell Medical College…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses What To Do With A Patient With Advanced CMML?…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Lenalidomide In High Risk MDS Patients at Lymphoma &…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses Hypomethylating Drugs & Mutations In MDS at Lymphoma &…
Lee Sangmin, M.D. Assistant Professor at Weill Cornell Medical College Discusses How Long To Treat With Azacitidine at Lymphoma &…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ELIQUIS(Apixaban) In Non Cancer Setting…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial: Upper Extremity &…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Overall Event Rates…
Adam Binder, M.D. Assistant Professor at Thomas Jefferson University Hospital Discusses Approving Vancomycin With Neutropenic Fever Patients At The 60th…
Shyamala Navada, M.D. Assistant Professor at Mount Sinai Health System Discusses Oral Rigosertib With Standard Dose Azacitidine At The 60th…
Robert McBane, M.D. Practicing Hematologist & Oncologist At The Mayo Clinic in Rochester, MN Discusses ADAM-VTE Trial Summary At The…
Filippo Milano, M.D., PhD Assistant Member Clinical Research Division, Associate Director Cord Blood Transplantation Cord Blood Program, Assistant Professor University…
Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Transfusion Independance With Hypomethylating agents At The 60th…
Amer Zeidan, MBBS Assistant Professor of Medicine (Hematology) at Yale University Discusses Is Patient Survival Based On Physician Experience At…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Valeria Santini, MD, of the University…
EZH2 mutations are associated with a poor prognosis in myelodysplastic syndromes (MDS). In this video, recorded at the 2018 Society…
Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting, held in Houston, TX, David Steensma, MD, of the…
Allogeneic stem cell transplantation (allo-SCT) is the only curative option for many patients with hematological malignancies. It is therefore crucial…
Autologous stem cell transplantation can prove to be safer in some instances compared with allogeneic transplantation for treating hematological malignancies,…
Aman Chauhan, MBBS, University of Kentucky shares Launching Phase 2 Trial In Multi-Center Fashion | Currently Evaluated in Bone Marrow…
Brian I. Rini, MD, Cleveland Clinic explains Adding Amino Modulators to Increase Efficacy | Starting to Get Complete Response Rates…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains First In-Class Agent Targeting PD-L1 & TGF-? | There Are…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Combining TGF-? & PD-L1 is Developing One Drug | Very…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Look at Single-Agent Activity in Larger Studies | Vaccines Combining…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains Analysis of HPV-Positive Malignancies | TGF-? Dysregulation is Seen in…
Ana Limon Carrera, Takeda Oncology, shares TAK-931 – A CDC7 Inhibitor in Solid Tumors | Dosage Collision Study Shows Treatment…
James L. Gulley, MD, PhD, FACP, National Cancer Institute, explains M7824 – Novel Bifunctional Protein | Anti-Body Targeting PD-L1, Sequester…
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood…
Thrombotic microangiopathy (TMA) is a rare complication that may arise post-transplant in patients, however, incidence of TMA has increased in…
The complications in blood and marrow transplantation can be serious with rapid onset, therefore ideal donor matching is crucial in…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Mohamad Mohty, MD,…
There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although…
The therapeutic landscape of Hodgkin lymphoma has improved considerably over the past 50 years, with patient outcomes improving due to…
Disease relapse is a significant cause of transplant failure in patients with acute myeloid leukemia (AML). Talking at the 2018…
Charles Craddock, CBE, FRCP (UK), FRCPath, DPhil, from University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, outlines the breakthrough therapies…
Cure Leukemia is a leading center for the development of new drug and transplant treatments for patients with hematological cancers.…
There is a desperate need for rapid turnaround of transplant clinical trials to bring forward breakthrough therapies. IMPACT is a…
Ruben Niesvizky, MD, explains Incorporating Different Schedules into Combinations Use minimum active dose at Imedex Great Debates 2018.
Ruben Niesvizky, MD, explains Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities at Imedex Great…
Paul G. Richardson, MD, explains Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib at Imedex…
Paul G. Richardson, MD, explains One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity at Imedex…
Paul G. Richardson, MD, explains Early Transplant Confers PFS Benefit, but Not Overall Stem cell transplant is an option at…
Paul G. Richardson, MD, explains Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone at Imedex Great Debates…
Paul G. Richardson, MD, explains RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids at Imedex Great Debates…
Hyperhydration is typically used along with high-dose melphalan in patients undergoing stem cell transplantation. However, the evidence behind this practice…
The European Society for Blood and Marrow Transplantation (EBMT) have recently set up their dedicated EBMT Patient Advisory and Advocacy…
Blood and bone marrow transplantation continues to experience breakthroughs, with the role of the patient becoming increasingly important. In this…
The Worldwide Network for Blood & Marrow Transplantation (WBMT) is an umbrella organization for institutions and centers carrying out blood…